image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 24.0
1.78 %
$ 1.11 B
Market Cap
-21.62
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 1, 2025.

The intrinsic value of one BLFS stock under the worst case scenario is HIDDEN Compared to the current market price of 24 USD, BioLife Solutions, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 1, 2025.

The intrinsic value of one BLFS stock under the base case scenario is HIDDEN Compared to the current market price of 24 USD, BioLife Solutions, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 1, 2025.

The intrinsic value of one BLFS stock under the best case scenario is HIDDEN Compared to the current market price of 24 USD, BioLife Solutions, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BLFS

image
$29.0$29.0$28.0$28.0$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.015 Sep15 SepOct '24Oct '2415 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 Feb
FINANCIALS
143 M REVENUE
-11.43%
-70.8 M OPERATING INCOME
-77.45%
-66.4 M NET INCOME
52.49%
-12.5 M OPERATING CASH FLOW
-47.23%
17.8 M INVESTING CASH FLOW
130.69%
10.6 M FINANCING CASH FLOW
-35.09%
30.6 M REVENUE
7.92%
-1.56 M OPERATING INCOME
44.22%
-15.3 M NET INCOME
26.27%
4.8 M OPERATING CASH FLOW
-25.65%
-1.68 M INVESTING CASH FLOW
87.49%
-1.04 M FINANCING CASH FLOW
-47.87%
Balance Sheet BioLife Solutions, Inc.
image
Current Assets 121 M
Cash & Short-Term Investments 51.7 M
Receivables 18.7 M
Other Current Assets 50.3 M
Non-Current Assets 292 M
Long-Term Investments 5.62 M
PP&E 32.6 M
Other Non-Current Assets 254 M
12.53 %4.52 %12.18 %7.90 %61.51 %Total Assets$412.7m
Current Liabilities 42.2 M
Accounts Payable 6.94 M
Short-Term Debt 10 M
Other Current Liabilities 25.2 M
Non-Current Liabilities 32.9 M
Long-Term Debt 32.7 M
Other Non-Current Liabilities 188 K
9.25 %13.33 %33.62 %43.55 %Total Liabilities$75.1m
EFFICIENCY
Earnings Waterfall BioLife Solutions, Inc.
image
Revenue 143 M
Cost Of Revenue 96.5 M
Gross Profit 46.8 M
Operating Expenses 118 M
Operating Income -70.8 M
Other Expenses -4.4 M
Net Income -66.4 M
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)143m(97m)47m(118m)(71m)4m(66m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
32.63% GROSS MARGIN
32.63%
-49.43% OPERATING MARGIN
-49.43%
-46.36% NET MARGIN
-46.36%
-19.67% ROE
-19.67%
-16.10% ROA
-16.10%
-18.66% ROIC
-18.66%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis BioLife Solutions, Inc.
image
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -66.4 M
Depreciation & Amortization 12.3 M
Capital Expenditures -6.38 M
Stock-Based Compensation 31.7 M
Change in Working Capital 1.47 M
Others 11.7 M
Free Cash Flow -18.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets BioLife Solutions, Inc.
image
Wall Street analysts predict an average 1-year price target for BLFS of $27.3 , with forecasts ranging from a low of $22 to a high of $30 .
BLFS Lowest Price Target Wall Street Target
22 USD -8.33%
BLFS Average Price Target Wall Street Target
27.3 USD 13.89%
BLFS Highest Price Target Wall Street Target
30 USD 25.00%
Price
Max Price Target
Min Price Target
Average Price Target
303028282626242422222020181816161414Apr '24Apr '24Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership BioLife Solutions, Inc.
image
Sold
0-3 MONTHS
641 K USD 5
3-6 MONTHS
3.18 M USD 7
6-9 MONTHS
370 K USD 5
9-12 MONTHS
1.45 M USD 8
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025 BOTHELL, Wash. , Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. prnewswire.com - 1 week ago
Recent Price Trend in BioLife Solutions (BLFS) is Your Friend, Here's Why BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com - 2 weeks ago
BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue? BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 1 month ago
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year? Here is how BioLife Solutions, Inc. (BLFS) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year. zacks.com - 1 month ago
BioLife Solutions (BLFS) Is a Great Choice for 'Trend' Investors, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, BioLife Solutions (BLFS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. zacks.com - 1 month ago
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded the high end of previously raised guidance BOTHELL, Wash. , Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced 2024 fourth quarter and full year preliminary unaudited revenue from continuing operations. prnewswire.com - 1 month ago
BioLife Solutions price target raised to $31 from $28 at Northland Northland raised the firm's price target on BioLife Solutions to $31 from $28 and keeps an Outperform rating on the shares. With the divestiture of its freezer businesses and the recent sale of SciSafe biostorage, the firm believes BioLife is positioned to "emerge as a leading consolidator in the sector" as the company refocuses on its core expertise in biopreservation media and cell processing products and services for cell and gene therapies, the analyst tells investors. https://thefly.com - 1 month ago
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors BOTHELL, Wash. , Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. prnewswire.com - 2 months ago
BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary Completes the Company's strategic move away from capital equipment businesses BOTHELL, Wash. , Nov. 14, 2024 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or "CBS"), for $6.1 million in cash. prnewswire.com - 3 months ago
BioLife Solutions, Inc. (BLFS) Q3 2024 Earnings Call Transcript BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Rod de Greef - Chairman and Chief Executive Officer Garrie Richardson - Chief Revenue Officer Conference Call Participants Matt Stanton - Jefferies Brendan Smith - TD Cowen Anna Snopkowski - KeyBanc Matt Hewitt - Craig-Hallum Capital Group LLC Thomas Flaten - Lake Street Capital Markets Jade Montgomery - H.C. Wainwright & Co., LLC Operator Good afternoon, ladies and gentlemen, and thank you for standing by. seekingalpha.com - 3 months ago
BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.67 per share a year ago. zacks.com - 3 months ago
BioLife Solutions Reports Third Quarter 2024 Financial Results Cell Processing revenue grew 6%  sequentially to $19.0 million; 43% increase compared to 2023 GAAP gross margin of 51%  and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestiture Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. prnewswire.com - 3 months ago
8. Profile Summary

BioLife Solutions, Inc. BLFS

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 1.11 B
Dividend Yield 0.00%
Description BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Contact 3303 Monte Villa Parkway, Bothell, WA, 98021 https://www.biolifesolutions.com
IPO Date Nov. 22, 1989
Employees 409
Officers Mr. Roderick de Greef Chief Executive Officer & Chairman Mr. Sean Werner Ph.D. Chief Technology Officer Mr. Todd Berard Chief Commercial Officer Ms. Karen Foster Chief Quality & Operations Officer Ms. Sarah Aebersold J.D. Chief Human Resources Officer Mr. Troy Wichterman CPA Chief Financial Officer Dr. Aby J. Mathew Ph.D. Chairman of Scientific Advisory Board, Executive Vice President & Chief Scientific Officer